Core Viewpoint - Profound Medical Corp. has increased the size of its private placement to raise up to US$6.45 million, accommodating a long-term existing investor [1]. Group 1: Offering Details - The Offering will consist of up to 921,428 common shares priced at US$7.00 per share [1]. - The common shares will be subject to a hold period of four months plus one day from the closing date, which is expected to occur on or prior to December 30, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the Offering will be utilized for expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes [2]. Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company that develops AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4]. - The company is commercializing TULSA-PRO, a technology that combines real-time MRI, AI-enhanced planning, and ultrasound for prostate disease treatment [5]. - Profound is also commercializing Sonalleve, a therapeutic platform for treating uterine fibroids and other conditions, with approvals in multiple jurisdictions [6].

Financing included participation by healthcare-dedicated investors alongside existing shareholdersTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, for gross proceeds of approximately $36 million before fees and expenses. The registered direct offering was structured as a straightforward equi ...

Core Viewpoint - Profound Medical Corp. announced a registered direct offering of 5,142,857 common shares at $7.00 per share, aiming for gross proceeds of up to $40 million, including a subsequent private placement of up to 571,428 shares at the same price [1][3][6] Group 1: Offering Details - The registered direct offering is structured as an equity investment with no warrant coverage, led by healthcare-dedicated investors [2] - Gross proceeds from the offering are expected to be approximately $36 million before deducting fees and expenses [3] - The private placement aims for up to $4 million in gross proceeds, with shares subject to a four-month hold period [6] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes [3] Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided therapies for tissue ablation [7] - The company is commercializing TULSA-PRO, a technology for treating various prostate conditions, which is incision-free and has a quick recovery time [8] - Profound is also developing Sonalleve, a platform for treating uterine fibroids and other conditions, with approvals in multiple jurisdictions [9]

Profound Medical (PROF) closed the last trading session at $6.75, gaining 15.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.31 indicates an 82.4% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $2.01. While the lowest estimate of $11.00 indicates a 63% increase from the current price level, the most optimistic analyst ...

Core Insights - Profound Medical Corp. announced that Dr. Pejman Ghanouni received the Cum Laude award for his presentation on the CAPTAIN trial comparing MRI-guided TULSA Procedure with robotic radical prostatectomy at the RSNA Annual Meeting 2025, highlighting the significance of this recognition in the medical community [1][2][3] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [5][6] - The company is commercializing the TULSA-PRO system, which utilizes real-time MRI and AI-enhanced planning for precise prostate tissue ablation, aiming to become a mainstream treatment for various prostate conditions [6][7] TULSA Procedure Details - The TULSA Procedure is a non-invasive treatment that uses robotically controlled ultrasound to ablate prostate tissue while preserving surrounding structures, offering advantages such as no blood loss, no overnight hospital stay, and quicker recovery times compared to traditional surgical methods [3][7] - The procedure is designed to be performed in a single session, taking a few hours, and is suitable for a wide range of prostate shapes and sizes [7] CAPTAIN Trial Insights - The CAPTAIN trial is a multi-center randomized controlled study comparing the safety and efficacy of the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk prostate cancer, with 210 patients randomized as of January 2025 [4] - The trial's results indicate that patients undergoing the TULSA Procedure experience significantly shorter recovery times, with many feeling back to normal the day after the procedure, compared to an average of three weeks for robotic surgery patients [3][4] Recognition and Awards - Dr. Ghanouni's presentation was one of only six to receive the Cum Laude award at RSNA 2025, representing the top 5% of scientific posters, underscoring the quality and impact of the research presented [2][3] - Additionally, Dr. Satoru Takahashi received a Certificate of Merit for his work on TULSA, further validating the procedure's emerging role in prostate cancer treatment [3]

Core Insights - The CAPTAIN trial is the first randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robotic radical prostatectomy (RP), successfully recruiting to target [1][4] - Dr. Pejman Ghanouni received the Cum Laude award for his presentation on the CAPTAIN trial at the RSNA Annual Meeting, highlighting the significance of the study [1][2] - The TULSA Procedure offers a quicker recovery time compared to robotic RP, with patients feeling better the day after the procedure, while robotic RP patients take nearly three weeks [3] Company Overview - Profound Medical Corp. specializes in AI-powered, MRI-guided, incision-free therapies for tissue ablation, with a focus on the TULSA Procedure [1][5] - The TULSA-PRO system is the only AI-powered, MRI-guided robotic system for prostate therapy, allowing real-time monitoring and personalized treatment [3][6] - Profound is also commercializing Sonalleve, a therapeutic platform for various conditions, including uterine fibroids and bone metastases [7] CAPTAIN Trial Details - The CAPTAIN trial is a multi-center study comparing the safety and efficacy of TULSA with RP in men with organ-confined, intermediate-risk prostate cancer [4] - As of January 2025, 210 patients were randomized, with 69% receiving TULSA and 31% receiving RP, ensuring balanced baseline characteristics [4] - The trial commenced in 2022 across 20 sites in the U.S., two in Canada, and one in Europe, with the last patient treatment occurring in August 2025 [4]

Core Insights - Profound Medical Corp. is launching the TULSA-AI Volume Reduction module for treating benign prostatic hyperplasia (BPH) at the RSNA meeting, enhancing the TULSA Procedure's versatility and potential for mainstream adoption [1][4] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for ablation of diseased tissue [9][10] - The TULSA Procedure™ is the only incision-free option for prostate cancer and BPH, utilizing real-time MRI guidance for precision [3][10] Product Details - The TULSA-AI Volume Reduction module allows for efficient stacking of multiple prostate cases in one day, improving workflow and reducing procedure times [3][4] - The TULSA Procedure has shown significantly reduced risks of sexual function loss and incontinence compared to traditional methods, with superior outcomes in blood loss, length of stay, post-operative pain, and recovery time [3][4] Market Potential - The launch of the TULSA-AI module is expected to triple Profound's total available market in prostate disease to approximately 600,000 patients annually [4] - The TULSA Procedure is positioned to become a mainstream treatment across various prostate disease conditions, including low-, intermediate-, and high-risk prostate cancer, as well as BPH [10] Event Participation - Profound Medical will showcase the TULSA-AI Volume Reduction module and present new clinical data at the RSNA and SUO meetings [5][6][7]

Core Viewpoint - Profound Medical (PROF) is showing potential as a bullish investment opportunity due to a recent technical indicator known as a "golden cross" [1][3]. Technical Analysis - PROF's 50-day simple moving average has crossed above its 200-day simple moving average, indicating a possible bullish breakout [1]. - A golden cross typically follows a downtrend, where the shorter moving average crosses above the longer moving average, leading to a positive trend reversal [2]. Performance Metrics - Over the past four weeks, PROF has experienced a price increase of 9.3% [3]. - The stock currently holds a 2 (Buy) rating on the Zacks Rank, suggesting it may be positioned for further upward movement [3]. Earnings Outlook - The earnings outlook for PROF is positive, with two upward revisions in earnings estimates over the past 60 days, and no downward revisions [3]. - The Zacks Consensus Estimate for the current quarter has also increased, reinforcing the bullish sentiment around the stock [3]. Investment Consideration - Given the significant technical indicator and the positive trend in earnings estimates, investors are encouraged to consider adding PROF to their watchlist [5].

Core Viewpoint - Profound Medical (PROF) has experienced a bearish trend, losing 12.3% in the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with reduced selling pressure, suggesting that bulls may be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that despite a downtrend, buying interest emerges to push the stock price up towards the opening price [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength is dependent on its placement on the chart [6]. Fundamental Analysis - Recent upward revisions in earnings estimates for PROF serve as a bullish indicator, correlating strongly with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 7.6%, indicating that analysts expect better earnings than previously predicted [8]. - PROF holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Profound Medical (PROF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on changes in earnings estimates, leading to significant stock price movements [4]. Company Performance and Outlook - The recent upgrade for Profound Medical suggests an improvement in its underlying business, which should encourage investors to drive the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for Profound Medical has increased by 6.2% [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating [9][10]. - Profound Medical's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].